Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | GNB2L1 |
| Gene Name: | GNB2L1 |
| Protein Full Name: | Guanine nucleotide-binding protein subunit beta-2- |
| Alias: | Cell proliferation-inducing gene 21 protein; GBLP; GNB2L1; GNB2-RS1; Guanine nucleotide binding protein (G protein) beta polypeptide 2-like 1; Guanine nucleotide-binding protein beta subunit-like protein 12.3; H12.3; Human lung cancer oncogene 7 protein; P205; Receptor for activated C kinase; Receptor for Activated C Kinase 1; Receptor of activated protein kinase C 1 |
| Mass (Da): | 35077 |
| Number AA: | 317 |
| UniProt ID: | P63244 |
| Locus ID: | 10399 |
| COSMIC ID: | GNB2L1 |
| Gene location on chromosome: | 5q35.3 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19718 |
| Percent of cancer specimens with mutations: | 0.22 |
| Normal role description: | GNB2L1 inhibits Src family kinases, stabilizes activated PKC, and interacts with many other proteins. May act as an adapter protein for a variety of proteins, including those of central cellular pathways in cell growth, migration and apoptosis. Involved in different functions in the nervous system. Promotes apoptosis by disrupting BAX interaction with BCL2L and BAX oligomerization. Hoewever upregulated expression of GNB2L1 was reported to inhibit apoptosis in lymphocytes. Shown to be upregulated during tumour angiogenesis. |
| Commentary on involvement of protein in cancer: | No mutations have been reported on the Atlas of Genetics in Oncology or the SANGER COSMIC database. |